Sabri, A., Mubarak, A. (2024). A Study in Clinicopathological Characteristics of Pancreatic Cancer Related Diabetes in Iraqi Patients. , 23(1), 31-38. doi: 10.52573/ipmj.2024.182849
Abdullah Ghazwan Sabri; Ahmed Mubarak Mubarak. "A Study in Clinicopathological Characteristics of Pancreatic Cancer Related Diabetes in Iraqi Patients". , 23, 1, 2024, 31-38. doi: 10.52573/ipmj.2024.182849
Sabri, A., Mubarak, A. (2024). 'A Study in Clinicopathological Characteristics of Pancreatic Cancer Related Diabetes in Iraqi Patients', , 23(1), pp. 31-38. doi: 10.52573/ipmj.2024.182849
Sabri, A., Mubarak, A. A Study in Clinicopathological Characteristics of Pancreatic Cancer Related Diabetes in Iraqi Patients. , 2024; 23(1): 31-38. doi: 10.52573/ipmj.2024.182849

A Study in Clinicopathological Characteristics of Pancreatic Cancer Related Diabetes in Iraqi Patients

Iraqi Postgraduate Medical Journal
Article 7, Volume 23, Issue 1, January 2024, Pages 31-38    PDF (550.12 K)
Document Type: Research Paper
DOI: 10.52573/ipmj.2024.182849
Authors
Abdullah Ghazwan Sabri* ; Ahmed Mubarak Mubarak
Medical oncology, Oncology Department, Al Yarmuk Teaching Hospital, Baghdad, Iraq
Abstract
ABSTRACT:
BACKGROUND:
Globally, pancreatic cancer is the 11th most common cancer in women and the 12th most common in men. Many studies have been done to reveal the relationship and the mechanism between diabetes and pancreatic cancer. Some revealed the relationship between diabetes and increased risks of pancreatic cancer in both males and females. Another revealed that new onset diabetes could potentially indicate early stage pancreatic cancer.
OBJECTIVE:
To determine the association between diabetes and clinic-pathological features of pancreatic carcinoma.
PATIENTS AND METHODS:
A case control study conducted in Baghdad Oncology Teaching Hospital and in Al-Amal National Hospital for the treatment of cancerous tumors during a period of nine months from April till the end of December 2020. It included 66 patients referred from GIT centers or any other surgical departments and newly diagnosed as pancreatic cancer and divided into two groups: Case group included 29 patients who were a known case of type 2 diabetes for at least one year and newly diagnosed with pancreatic cancer and control group included 37 patients newly diagnosed with pancreatic cancer but had no diabetes.
RESULTS:
In this study, no significant difference between the study groups in regards to the mean of Ca19.9 level. Diabetes was significantly associated with increase rate of Hypertension among pancreatic cancer patients. Diabetic patients were with shorter PFS and higher incidence of progression than non-diabetic patients were.
CONCLUSION:
Diabetes is not only one of the causes of pancreatic cancer but also as a complication of pancreatic cancer. Diabetic patients are associated with hypertension, worse survival and diabetes can be a predictive factor in pancreatic cancer survival.
 
Keywords
Pancreatic cancer; diabetes; clinic pathological; Iraq
References
  1. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. New England Journal of Medicine. 2014;371:1039-49.
  2. De Luca L, Repici A, Koçollari A, Auriemma F, Bianchetti M, Mangiavillano B. Pancreatoscopy: An update. World journal of gastrointestinal endoscopy. 2019;11:22.
  3. Maitra A, Sharma A, Brand RE, Van Den Eeden SK, Fisher WE, Hart PA, et al. A Prospective Study to Establish a New-Onset Diabetes (NOD) Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas. 2018;47:1244.
  4. Song S, Wang B, Zhang X, Hao L, Hu X, Li Z, et al. Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: a meta-analysis. PloS one. 2015;10:e0134321.
  5. Barone E, Corrado A, Gemignani F, Landi S. Environmental risk factors for pancreatic cancer: an update. Archives of toxicology. 2016;90:2617-42.
  6. Sah RP, Nagpal SJS, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nature reviews Gastroenterology & hepatology. 2013;10:423.
  7. Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54:643-49.
  8. Eissa AH. Carcinoma of The Pancreas A Retrospective Study of Pancreatic Cancer of 320 Case from 1976 to 2011. Medical Journal of Babylon. 2014;11.
  9. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 2011;22:189-97.
  10. Antwi SO, Oberg AL, Shivappa N, Bamlet WR, Chaffee KG, Steck SE, et al. Pancreatic cancer: associations of inflammatory potential of diet, cigarette smoking and long-standing diabetes. Carcinogenesis. 2016;37:481-90.
  11. Ben Q, Xu M, Jiang Y, Yuan Y, Wang K, Fang J, et al. Clinical profiles and long-term outcomes of patients with pancreatic ductal adenocarcinoma and diabetes mellitus. Diabetes/Metabolism Research and Reviews. 2012;28:169-76.
  12. Mizuno S, Nakai Y, Isayama H, Takahara N, Miyabayashi K, Yamamoto K, et al. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Pancreatology. 2013;13:285-89.
  13. Li W, Ma Q, Li J, Guo K, Liu H, Han L, et al. Hyperglycemia enhances the invasive and migratory activity of pancreatic cancer cells via hydrogen peroxide. Oncology reports. 2011;25:1279-87.
  14. Rozengurt E. Mechanistic target of rapamycin (mTOR): a point of convergence in the action of insulin/IGF-1 and G protein-coupled receptor agonists in pancreatic cancer cells. Frontiers in physiology. 2014;5:357.
  15. Bishop J. Cancer facts: CRC Press; 1999.
  16. Amin S, Mhango G, Lin J, Aronson A, Wisnivesky J, Boffetta P, et al. Metformin improves survival in patients with pancreatic ductal adenocarcinoma and pre-existing diabetes: a propensity score analysis. The American journal of gastroenterology. 2016;111:1350.
  17. Mao Y, Tao M, Jia X, Xu H, Chen K, Tang H, et al. Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Sci Rep. 2015;5:17102.
  18. Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, et al. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. Gastroenterology. 2018;155:479-89.e7.
  19. Dong Y-W, Shi Y-Q, He L-W, Cui X-Y, Su P-Z. Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget. 2017;8:55478-88.
  20. Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical cancer research. 2012;18:2905-12.
  21. Zechner D, Bürtin F, Albert AC, Zhang X, Kumstel S, Schönrogge M, et al. Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin. Oncotarget. 2016;7:56395-407.
  22. Ding X-Z, Fehsenfeld DM, Murphy LO, Permert J, Adrian TE. Physiological concentrations of insulin augment pancreatic cancer cell proliferation and glucose utilization by activating MAP kinase, PI3 kinase and enhancing GLUT-1 expression. Pancreas. 2000;21:310-20.
  23. Busaidy N, Yazbeck C, Shah P, Evans D, Li D, Geraci J, et al. Survival of resectable pancreatic cancer patients with diabetes. Journal of Clinical Oncology. 2006;24:4098.
 

Statistics
Article View: 309
PDF Download: 141


Journal Management System. Powered by iJournalPro.com